Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
Gail J Roboz, H Jean Khoury, Elias Jabbour, Wilena Session, Ellen K Ritchie, Harry Miao, Stefan Faderl, Wei Zheng, Eric J Feldman, Martha Arellano, J Gilmour Morrison, Farhad Ravandi, Gail J Roboz, H Jean Khoury, Elias Jabbour, Wilena Session, Ellen K Ritchie, Harry Miao, Stefan Faderl, Wei Zheng, Eric J Feldman, Martha Arellano, J Gilmour Morrison, Farhad Ravandi
Abstract
There is no effective treatment for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a phase I dose escalation trial of SAR103168, a novel multi-targeted kinase inhibitor with activity against the Src kinase family, the BCR-Abl kinase and several angiogenic receptor kinases. Twenty-nine patients 18-83 years old were treated with SAR103168. Pharmacokinetics was characterized by plasma peak concentration (Cmax) at the end of the infusion, followed by a biphasic decline in the elimination profile. Adverse events were as expected for the patient population and there were no individual toxicities specific to SAR103168. Due to the unpredictable nature of drug exposure, the sponsor decided to discontinue the study prior to reaching the maximum tolerated dose.
Trial registration: ClinicalTrials.gov NCT00981240.
Keywords: AML; MDS; SAR103168; multi-kinase inhibitor.
Figures
Source: PubMed